Naor Nir 4

What Happened Naor Nir, a director of BrainStorm Cell Therapeutics, was granted 180,000 stock options on February 26, 2026. The options have a $0.70 exercise price, representing a notional acquisition value of $126,000 (180,000 x $0.70). This transaction is an award of derivative securities (options), not an immediate purchase of common shares.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-05-20 (late filing).
• Award: 180,000 options under the Issuer's 2014 Stock Incentive Plan (footnote F1).
• Exercise price: $0.70 per share; reported aggregate value: $126,000.
• Vesting (footnote F2): 50% vest on grant date; remaining 50% vests on the six‑month anniversary, contingent on continued service.
• Shares owned after transaction: not specified in the supplied filing excerpt.
• Transaction code: "A" — award/grant of derivative securities.
• Filing timeliness: The Form 4 was filed nearly three months after the grant date; late filings reduce prompt transparency but do not alter the underlying award.

Context These are stock options (derivatives) that become shares only if and when exercised. Because 50% vested immediately, Nir can exercise up to 90,000 options upon grant (subject to plan rules and any blackout/tax considerations); the remaining 90,000 vest after six months if he remains employed. There is no indication in the filing of an exercise or any immediate sale of underlying shares.